CRISPR Screens Reveal Genetic Determinants of PARP Inhibitor Sensitivity and Resistance in Prostate Cancer

Scientists performed genome-wide CRISPR-Cas9 knockout screens in BRCA1/2-proficient prostate cancer cells and identified previously unknown genes whose loss had a profound impact on poly (ADP-ribose) polymerase inhibitor response.